Table 3.
Antibiotic | MRSA | S epidermidis | VRE | K pneumoniae | E coli |
---|---|---|---|---|---|
Linezolid | 21 ± 0.75* | 29 ± 0.5* | 15 ± 4.6* | Resistant | Resistant |
Gentamicin | Resistant | 5 ± 1.7 | Resistant | 10 ± 1.73 | 16 ± 2 |
Vancomycin | 8 ± 0.5 | 19 ± 1.9 | Resistant | Resistant | Resistant |
Linezolid ± gentamicin | >45† | 38 ± 0.95† | 32† | >45 | 40 ± 0.5 |
Linezolid ± vancomycin | 31±10‡ | >45‡ | 17 ± 1.15 | Resistant | Resistant |
These values are significantly longer (P < 0.01) compared with those of vancomycin for respective bacteria
These values are significantly longer (P < 0.01) compared with those of vancomycin, linezolid or gentamicin alone for respective bacteria
These values are significantly longer (P < 0.01) compared with those of either vancomycin or linezolid alone for respective bacteria
MRSA, methicillin‐resistant Staphylococcus aureus; VRE, vancomycin‐resistant enterococci.